A B S T R A C T The minimum inhibitory concentration (MIC) of adenine arabinoside (ara-A) in rabbit kidney microtiter tissue cultures (RK-13) to a prototype strain of herpes simplex virus, type 1 (E115) based upon inhibition of cytopathic effects is 1.5 ,ug/ml. In this system, the MIC of arabinosylhypoxanthine (araHx), the major in vivo metabolic derivative of ara-A, is 75 4g/ml. 
A B S T R A C T The minimum inhibitory concentration (MIC) of adenine arabinoside (ara-A) in rabbit kidney microtiter tissue cultures (RK-13) to a prototype strain of herpes simplex virus, type 1 (E115) based upon inhibition of cytopathic effects is 1.5 ,ug/ml. In this system, the MIC of arabinosylhypoxanthine (araHx), the major in vivo metabolic derivative of ara-A, is 75 4g/ml. Inhibition of cytopathic effects of herpes simplex virus, type 1 (HSV-1) in microtiter wells of RK-13 cells varies directly with the concentrations of ara-A or ara-Hx, and inversely with residual HSV-1. The MIC of ara-A for HSV-1 in RK-13 cells is 5-20 times lower than similar measures with vero renal, mouse embryo, or human foreskin cultures. With RK-13 tissue cultures in microtiter plates, an assay for "ara-A equivalents" in human body fluids was developed which compares in sensitivity with high pressure liquid chromatography and has the advantage of simultaneously measuring combined antiherpesvirus effects of ara-A and its major metabolic derivative, ara-Hx.
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In vitro checkerboard studies in RK-13 cells confirmed that ara-A and ara-Hx in combination had antiviral effects which are synergistic. The total of the fractional MIC of ara-A plus ara-Hx in combination also varies inversely with residual HSV-1 in microtiter wells. Because virus adsorption is complete at 2 h before specimens to be tested are added in this assay, and because human interferon is not measured in rabbit cells, the antiviral assay is not affected by the presence of type-specific antiherpesvirus antibody or human interferon.
Antiviral activity (AVA) was assayed as ara-A equivalents in sera and urines from 10 patients with serious herpesvirus infections who received 2.5-20 mg/kg daily of ara-A by intramuscular or intravenous routes. When a dosage schedule of 10 mg/kg per day or more was used, sustained concentrations of AVA that ranged from 0.8 to 14.4 ,ug/ml were found. When an inhibitor of adenosine deaminase (covidarabine) was not added to the specimens, mean serum concentrations were =3.0 jig/ml (10 mg/kg per day, i.v.), and 4.1 ,ug/ml (20 mg/kg per day). However, in a single patient given 20 mg/kg of ara-A daily with covidarabine immediately added to the sera, the mean concentration of AVA was 12.9 ,ug/ml. Urines contained even higher AVA. Assays of 19 sera were performed both by microbiologic assay for AVA and by high pressure liquid chromatography for ara-A and ara-Hx. AVA was greater by microbiologic assay, and was greater than that which could be accounted for by stoichiometric chromatographic measures of ara-A and ara-Hx. These results with sera of treated patients are consistent both with the in vitro synergy ofara-A and ara-Hx found by checkerboard titrations, and with the beneficial responses to ara-A of patients with herpesvirus infections reported here and elsewhere. INTRODUCTION Adenine arabinoside (9-,B-D arabinofuranosyladenine, ara-Al, or vidarabine) is an effective antiherpesvirus agent. Ara-A is therapeutic for patients with keratouveitis (1) and encephalitis (2) caused by herpes simplex viruses as well as in disseminated varicella-zoster in the immunosuppressed (3) . Controlled trials of ara-A in neonatal herpes simplex virus encephalitis are not yet complete (4, 5) . Results have been less promising in variola major (6) and cytomegalovirus infections (7) .
In the past, this laboratory's biological assays of pharmacokinetics of ara-A in human body fluids have been too insensitive to be useful (8) , and correlations of clinical experience and concentrations of drug have depended upon chemical studies (9, 10) . In this regard, our earlier microbiologic assays of human body fluids had a sensitivity of =20 ,ug/ml of ara-A. When used, only 1 of84-sera from patients who had received up to 20 mg/kg i.v. daily had detectable concentrations (8) . We now report results of reassaying these same specimens by a new method with a sensitivity of 1.5 ,ug/ml of ara-A.
METHODS
Administration of ara-A and collections of specimens. After informed consent, 10 patients with various herpesvirus infections were given ara-A for 5-10 days in graded doses from 2.5 to 20.0 mg/kg per day by i.m. (2 patients) or i.v. routes. Ara-A was infused intravenously at rates of mg/h. Diagnoses were severe recurrent genital herpes simplex virus, type 2 infection, 1 patient; disseminated HSV-1 infection, 2 patients; severe localized varicella-zoster (V-Z) infection, 2 patients; congenital cytomegalovirus infection, 1 patient; disseminated V-Z infection, 2 patients; chicken pox, 1 patient; and HSV-1 encephalitis, 1 patient. Single daily i.m. injections were given to two patients, and others received continuous i.v. infusions in 5% glucose solutions at a ratio of .2 ml/mg. Intravenous infusions of ara-A were given at rates varying from 16 to 75 mg/h for 5-10 days (Table I) . Intravenous infusions were given continuously but the rates of administration were not otherwise specifically controlled. Before ara-A infusions were begun, samples of blood and urine were collected from each patient. No antiviral activity (AVA) was detected in these specimens. In previous studies, we had shown that measures of AVA as determined here were unaffected by neutralizing antibody when specimens were added after absorption of virus was complete (e.g., 2 h later) (11) . At intervals, thereafter, bloods were taken, refrigerated (4°C) until clotted, and sera were separated. Bloods from patients 1-9 were handled promptly. With patient 10, 50 ,ug of an inhibitor of adenosine deaminase2 (co-ara-A or covidarabine, DI) was 'Abbreviations used in this paper: ara-A, adenine arabinoside; ara-Hx, arabinosylhypoxanthine; AVA, antiviral activity; CPE, cytopathic effects; HPLC, high pressure liquid chromatography; HSV-1, herpes simplex virus, type 1; MIC, minimum inhibitory concentration(s); TCD5O, fifty percent tissue culture dose; V-Z, varicella zoster. added for each 10 ml of whole blood (12, 13) .3 When covidarabine was added in this concentration, it had no AVA (12) . Total urinary collections in 4-to 6-h aliquots were also saved (40C). Until assay, sera and urines were stored (-20°C).
Clinical findings. During infusions of ara-A, hematologic (hemoglobin, hematocrit, total leukocyte and differential counts, erythrocytic indices, and platelet count), serum aspartate aminotransferase, serum alanine aminotransferase liver (alkaline phosphatase, cholesterol, prothrombin time, and albumin), and renal (creatinine and blood urea nitrogen) functions were tested every 2nd day. Thereafter, tests were followed less frequently. Patients were examined daily by us. Standard electrocardiograms were done every 3rd day.
When considering cutaneous V-Z or herpes simplex virus infections, the disease was considered disseminated when 20-100 vesicles appeared at sites different from the primary dermatome(s); or with congenital cytomegalovirus infection, when evidence of liver dysfunctions appeared. No patient received ara-A and concomitant radiation or cytotoxic drugs. Corticosteroids were continued at maintenance dosages during treatment with ara-A if needed for the primary underlying conditions. Cutaneous lesions were considered to have cleared when crusts had fallen off, leaving erythematous macules.
Virologic and antibody methods. Isolation, passage, and quantitation of HSV-1 and V-Z viruses; immunotyping of strains and meaures of micro-passive hemagglutinating, complement fixing, and indirect immunofluorescent antibodies have been described in detail earlier (14, 15 (11) . Unabsorbed virus was then decanted. Before inoculations, specimens were diluted with Eagle's minimum essential medium containing 2% fetal calf serum, and a final concentration of 10 ,ug/ml of co-ara-A was added. Covidarabine at this concentration had no antiviral activity (12) . 0.1 ml of diluted specimens was added to each well. Serum was diluted beginning at 1:2, urine starting at 1:5. Each day, experiments had wells with known concentrations of ara-A. MIC for ara-Hx were 75-150 ji.g/ml. Concentrations of 6.0 ,ug/0.1 ml (ara-A) and 30 ,ug/0.1 ml (ara-Hx) were toxic to RK-13 cells. However, at MIC for ara-A, there was only 0. 15 ,Ag/0. 1 ml ofara-A and 7.5-15 Ag/0. 1 ml ofara-Hx, and these concentrations did not visibly alter the tissue cultures. Wells containing ara-A and ara-Hx also contained coara-A. After all wells were inoculated, plates were again sealed and incubated (37°C) for 48 h. 3 Unfortunately, co-ara-A was not available to add to the bloods from patients 1-9. 4 To correlate inhibition of CPE with decrements in herpes simplex virus replication as a result of ara-A or ara-Hx, the following experiments were done. Routine MIC in RK-13 microtiter plates were run with ara-A and ara-Hx. At 48 h and before staining with paragon-formalin, cells and fluids from three wells each of virus and cell controls, as well as every concentration of ara-A (or ara-Hx) were scraped and pooled. Cell-fluid mixtures were rapidly freeze-thawed (three times) in acetone and dry ice, and titered for residual TCD50 of HSV-1 in RK-13 microtiter plates as before (Fig. IC) . In these tests, the MIC to ara-A was again 1.5 Ag/ml, and for ara-Hx it was 75.0 ug/ml. The virus control titered 105 5/0.1 ml.
With ara-A, pooled titers were 102 5 TCD.}0.1 ml at an ara-A concentration of0.6 ,hg/0.1 ml; 103 5 TCD5/0.lml at 0.3 ,ug/0.1 ml; 1045 TCD5J0.1 ml at 0.15 ,ug/0.1 ml; 1053 TCD50/0.1 ml at 0.08 ,ug/0.1 ml; 105.5 TCD5d0. 1 ml at 0.04 ,ig/0. 1 ml; and 105-5 TCD5d0O.1 ml at 0.02 ,ug/0.1 ml.
For ara-Hx, the virus control titered 10' 3/0.1 ml, there were 101-5, 104-5, 105.8, 1058, and 106-3 TCD5J0.1 ml at concentrations of antiviral compound of 15, 7.5, 1.8, 0.9, and 0.4 ,ug/0.1 ml, respectively (Fig. 2) . In this experiment, 15 i.g/ml of araHx was not toxic to cell cultures. Thus, the titers of residual herpes simplex virus varied inversely with the concentrations of ara-A and ara-Hx in the pooled microtiter wells (Fig. 2) . Cell controls contained no HSV-1. Therefore, in tests for MIC ofara-A and ara-Hx inhibition of CPE correlated with decreasing replication of herpes simplex virus in RK-13 tissue cultures ( Figs. 1 and 2) .
Estimations of the concentrations of AVA in patient specimens were made by calculations from the standard curve of that day's experiments considering the dilutions. Actual concentrations of AVA were, thus, measured per 0.1 ml, but are here expressed per milliliter. The sensitivity of the method was 1.5 ,ug/ml for ara-A and 75-150 ,ug/ml for ara-Hx (16) . Standard curves with known amounts of ara-A and ara-Hx were repeatedly reproducible as reported earlier with 5-iodo-2'-deoxyuridine (11) .
Each of the specimens of serum and urine which is reported here was run in duplicate, and each was repeated three times on separate days. Results by microbiologic assay were completely reproducible. In humans, ara-A is rapidly deaminated by adenosine deaminase to its hypoxanthine derivative, and sera, shortly after dosing, contain mostly ara-Hx, probably in combination with smaller amounts ofara-A (9, 10). The RK-13-method measures combined antiherpesvirus activity of the two antiviral compounds which we define as "ara-A equivalents" (Fig. 1) . High pressure liquid chromatography. Of the 77 specimens of sera assayed microbiologically here, 52 had been previously analyzed for ara-A and(or In vitro microbiological assays ofara-A and ara-Hx in combination. When initial results of assays of AVA in patients' sera and urines yielded AVA which was greater than that predicted by HPLC, checkerboard titrations of fractions of the MIC of ara-A with ara-Hx in combination were done in RK-13 microtiter plates. Concentrations of ara-A and ara-Hx used in vitro in combination were well below those producing toxic cytopathology. MIC to ara-A and ara-Hx were also done in human serum with a high titer of passive hemagglutinating antibodies to HSV-1.
RESULTS
In vitro checkerboard assays of ara-A and ara-Hx in combination. A typical checkerboard titration in microtiter RK-13 plates with 103.5 TCD,}0.1 ml of HSV-1 (E115) with combinations of ara-A and ara-Hx is shown in Table II . A decrease in CPE from 4+ to 2+ is considered to represent AVA. the minimum quantity of ara-A which, when combined with ara-Hx, showed AVA was 0.02 ,ug/0.1 ml of ara-A combined with 1.8 gg/0.1 ml of ara-Hx. Thus, in this titration, 0.13 MIC of ara-A plus 0.25 MIC of ara-Hx equaled AVA equal to 1 MIC. The total of these fractional MIC for ara-A and ara-Hx required to yield AVA of 1 MIC of either compound was, thus, 0.38 (0.13 plus 0.25). The "bonus" yield in AVA is 1-0.38 or 0.62 MIC. We express this "bonus" as the "sparing factor". By earlier convention, a "sparing factor" .0.5, we define as antiviral synergy (17) .
Again, to show that inhibition of CPE of combinations of the fractions of MIC of ara-A and ara-Hx correlated with inhibition of virus multiplication, virus control and residual virus from wells with synergistic Antiherpesvirus Activity in Humans after Adenine Arabinoside 1145. .:
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:-e,^ir g FIGuRE 2 Correlation of CPE of HSV-1 in microtiter plates of RK-13 cells and concentrations of ara-A and ara-Hx. Titrations in microtiter plates of MIC determined by inhibition of CPE as described in the text are correlated with titers of residual HSV-1 (E115). The MIC for ara-A was 0.15 ,ug/0.1 ml (1.5 jug/ml) and for ara-Hx, it was 7.5 ,ug/0.1 ml (75 ,ug/ml). As can be seen for both ara-A and ara-Hx, the concentration of antiviral agent varies inversely with residual HSV-1. Inhibition of CPE also correlates inversely with residual HSV-1.
effect, similar checkerboard titrations were repeated six times (Table III) . The mean of the fractional MIC of the six repititive checkerboard titrations was 0.46, with a mean "sparing factor" of 0.54. A Student's t test was done comparing the sum of 0.5 of the MIC of ara-A and ara-Hx with the fractional MIC needed to yield 1 MIC. The combinations required were significantly different (P s 0.05).
We repeated the MIC to ara-A and ara-Hx diluted in whole human serum with a passive hemagglutinating antibody titer to HSV-1 of 1:320. Values were unchanged, e.g., 1.5 and 75 ug/ml, respectively. These data again indicate that antiherpes simplex virus antibodies do not affect this AVA, and that neither ara-A nor ara-Hx is significantly bound to serum proteins. Antiviral activity in sera. Of85 sera from 10 courses of ara-A assayed by the microtiter method in RK-13 tissue cultures, 56 contained AVA (Table IV) . Concentrations in positive samples ranged from 0.8 to 14.4 ,ug/ ml of ara-A equivalents. AVA was found in sera from 9 of the 10 patients, and only three sera were available in the single patient in whom no AVA was de- ,ug/0.1 ml) and for ara-Hx, it was 75 ,tg/ml (0.75 jLg/0.1 ml).
For instance, if the combination was Vs MIC ara-A plus V4 MIC ara-Hx; 0.0188 ,ug ara-A plus 0.938 ,ug ara-Hx/0.1 ml would be present in these microtiter wells. tected (Table IV , patient 4). A mean of 1.7 ,ug/ml AVA was found in this single patient's urine, however. Intramuscular ara-A5 at doses of 2.5 and 5 mg/kg daily was given to two patients; 12 of these sera were positive with peaks as high as 6.0 ,tg/ml occurring 4-6 h after injections. At 12 h, AVA was low to undetectable. Arithmetic mean concentrations were 1.1 ,ug/ml in a 29-yr-old man (2.5 mg/kg per day), and 0.6 ,ug/ml in a 9-yr-old boy (5.0 mg/kg per day). The single patient given continuous i.v. infusions of 10.0 mg/kg of ara-A daily had 3.0 ,ug/ml AVA within 1 h after beginning 5Ara-A monophosphate may be better absorbed intramuscularly than ara-A, but this derivative was not available. therapy, and this same concentration was found later in the course as well (Table IV, Fig. 4) .
We found AVA in 39 of 55 sera from the 7 patients treated intravenously with 20 mg/kg of ara-A per day. AVA ranged from 0 to 14.4 ,ug/ml, with a mean of 4.1 /Ag/hnl (Table IV) . In general, AVA approached this mean conicentrationi within a few hours after the initiation of ara-A and persisted throughout the course of therapy.
The variation in AVA here by microbiologic assay with a given dosage demands comment. With a single exception (Table I , patient 9) azotemia was not present, and decreases in renal function cannot account for the variations in AVA in serum. Variations in concentrations of AVA mav be a resuilt of the followving factors. First, although ara-A was infused as a continuous intravenous drip, no special precautions were taken to insure that the rate of delivery was, in fact, constant, and, in all likelihood, it was not. Second, and most importantly, adenosine deaminase which rapidly converts ara-A to ara-Hx is present in human blood, anid because an inhibitor of this enzyme could not be added immediately to most of our specimens, a variable metabolism of ara-A in serum continued in vitro (18) . Indeed, in patient 10, to whose specimens covidarabine was promptly added, variation in AVA was markedly less, ranging from 7.2 to 14.4 ,ug/ml of "ara-A equivalenits". In this patient, the mean concentration was 12.9 ,ug/ml, while in 6 others also receiving a dose of 20 mg/kg of ara-A, mean AVA ranged from 0 to 5.8 p.g/ml. In this regard, samples of serum from patient 10 (as with all of the others) taken before beginning ara-A, both with and without covidarabine, showed no AVA. t Immediately after collection in this patient, 50 4g of an inhibitor of adenosine deaminase (covidarabine, DI) was added for each 10 ml of whole blood.
Comparisons of AVA in sera by microbiologic antd chemical assays. Concentrations of ara-A by HPLC and measures of AVA as ara-A equivalents were done in 52 sera (Table V) . Neither method found drug in 10 specimens. In each case where both methods were positive (3 times), the microbiologic assay of AVA exceeded chemical determinations of ara-A and ara-Hx. These differences could well result from the combined "bonus" effects described here for ara-A and ara-Hx in RK-13 tissue cultures which are measured microbiologically, but not chemically.
On the other hand, on 8, no.-6)6 had 0.2 ug/m ,ug/ml of ara-Hx, but no ara-A and ara-Hx are just microbiologic assay (Tab 6 This serum was drawn ara-A. This is a random sy venous infusion of 20 mg/k I l te specimen (Table V, Day of Treatment FIGUREs 4 and 5 Concentrations of equivalents of ara-A in sera after parenteral dosing; and urinary excretion of ara-A equivalents after parenteral dosing. AVA as ara-A equivalents in sera and urines of patients receiving intramuscular or intravenous ara-A daily is shown. Covidarabine was not added to these specimens. The dots represent individual determinations, bars are arithmetic means, and patients' ages (yr) are shown in parentheses (Fig. 4) . Urine values (Fig. 5) are concentrations per total collections over periods of 4 h. (Fig. 5) . Unfortunately, urines were not systematically collected after completion of treatment, but a single patient had 7.5 ,ug/ml of AVA in a random urine 7 days after completing an 8-day course (20 mg/kg per day, i.v.). We could not calculate urinary clearances, nor percents of drug excreted in urine because AVA does not correlate stoichiometrically with moles of either ara-A or ara-Hx.
Clinical findings. Within 9 days after ara-A was begun, every patient, with the possible exceptions of the infant with congenital cytomegalovirus infectioni and the 63-yr-old man with herpes simplex virus encephalitis, improved (Table I) . Patients 2 arid 8 with disseminated herpes simplex virus infections appear to have had the course of their infections dramatically improved, while the others recovered more slowly.
Toxic reactions. No significant changes in liver, kidney, or cardiac functions occurred. Hematologic changes were noted most often in patients with concomitant underlying chronic diseases and with 20-mg/kg doses of ara-A daily. Each ofthe six patients receiving 20 mg/kg per day of HPLC (10 ara-A had falls in hemoglobin of >2 g/100 ml, while measuring only one of the three patients receiving 10 mg/kg per the benefi day had a similar fall. Bone marrows were not examined fully obser in any of these patients, but in others megaloblasts gistic antiv have been seen. In three patients at the time ara-A fact probab was begun, platelets were <150,000/mm3, leukocyte cal and mic counts were <4,500/mm3, and absolute polymorpho-here. Simi nuclear numbers were <2,500/mm3. With The pharmacokinetic findings reported here add sig-gard, with nificant information to our understanding of the anti-virus (herp viral effects of ara-A in humans. AVA by this micro-and ara-A biologic assay with a sensitivity of 1.5 ,ug/ml of ara-A demonstrat equivalents is dependent upon antiherpesvirus activity The mec of ara-A and ara-Hx. The assay adds the specimen to be viral drugs tested for AVA after the complete absorption of the hibits herp virus challenge, and thus is not affected by the con-action of a] comitant presence of homotypic antibody in sera. LikeAt an i.v wise, the use of heterologous rabbit cells frees the equivalent' assay from interference by human interferon (11) .
therapy at This new microbiologic assay of AVA as a result of patient to v parenteral administration of ara-A is based upon the in-promptly a hibition of CPE of HSV-1. The method correlates with to its hypo3 the observed in vitro inhibition of HSV-1 multiplica-immediate tion, and the therapeutic effectiveness of ara-A. Earlier ara-A was inhibitor of adenosine deaminase or radioactive labeling techniques (9) single nucleosides have not predicted its to patients which have been careved. Combined, ara-A and ara-Hx are syneriral agents in RK-13 cells in vitro, and this ly accounts for differences between chemicrobiologic assays in vivo which are reported ilarly, antiviral synergy has already been vero renal cells with several strains of HSV-1 Land human interferon (17) , but a similar ins to be demonstrated in vitro in human tises. Indeed, AVA of drugs in combination early defined for each system by specifying hallenge, (b) its titer, and (c) the cell system y then can results of microbiologic assays fferent laboratories be compared. In this re-L different tissue cultures with a different )es simplex virus, type 2), human interferon in human skin fibroblast cultures do not te antiviral synergy (18, 19) . 2hanism of the combined effects of the anti-, ara-A and ara-Hx are unknown. Ara-A inesvirus polymerase (20, 21) , but the mode of ra-Hx is not clear.
dosage of 20 mg/kg per day AVA, as ara-A .s, was maintained throughout the course of a mean level of 12.9 Ag/ml in the single whose specimens of blood covidarabine was dded to inhibit in vitro degradation of ara-A xanthine derivative. When covidarabine was ly added to bloods, and 20 mg/kg per day of given, the mean concentration in serum was Antiherpesvirus Activity in Humans after Adenine Arabinoside 1151 4.1 ug/ml. Significant persisting serum AVA as a result of ara-A and ara-Hx contrasts remarkably with the transient or insignificant values which we found in patients receiving earlier candidate antiviral drugs, cytosine arabinoside and idoxuridine (8, 11, 22) . Sustained antiherpesvirus therapeutic concentrations in human sera correlate with the salutary effects of courses of ara-A reported in patients with herpes zoster and herpes simplex virus encephalitis (2, 3) . Urinary excretion of parenterally administered ara-A is estimated as 52%, but the half-life of ara-A has not yet been determined by chemical studies (10) . Ara-A is taken up by cells and the erythrocyte has been best studied to date (9) . The site of action of ara-A is, of course, intracellular, probably after phosphorylation (9, 20 
